Johnson & Johnson (JNJ) Tops Q3 EPS by 15c; Raises Outlook

Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.66, $0.15 better than the analyst estimate of $2.51. Revenue for the quarter came in at $21.4 billion versus the consensus estimate of $21.04 billion.

GUIDANCE:

Johnson & Johnson sees FY2023 EPS of $10.07-$10.13, versus the consensus of $10.03. Sees Adjusted Operational Sales up 7.2-7.7%, versus prior of 6.2-7.2%.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance